Initial Beneficial Ownership · 3
AgomAb Therapeutics NV
Initial Beneficial Ownership
Structured filing — 3
tm2625420-2_3seq1.xml
Filing details
- Report period
- 2026-09-11
- Issuer
- AgomAb Therapeutics NV
- Issuer CIK
- 0002020932
- Trading symbol
- AGMB
- No securities owned
- Checked
Reporting owner 1
- Name
- Garcia Marino
- Reporting owner CIK
- 0001669866
- Relationship
- Director
- Address
- AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERPEN, BELGIUM, C9, 2600
Remarks
Exhibit 24 - Power of Attorney
Signature 1
- Signed
- /s/ Ellen Lefever, Attorney-in-Fact
- Date
- 2026-09-15
Filed exhibits
- EXHIBIT 24 ↗tm2625420d2_ex24.htm
Company context
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.